P-347 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Transarterial Chemoembolization Combined with Durvalumab or Durvalumab Plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

B. Sangro,M. Kudo,S. Qin,Z. Ren,S. Chan,E. Joseph,Y. Arai,H. Mann,S. Morgan,G. Cohen,R. Lencioni

DOI: https://doi.org/10.1016/j.annonc.2020.04.429

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locoregional therapy such as transarterial chemoembolization (TACE) because curative therapy is not always an option and there is no standard systemic therapy. TACE therapy achieves tumor responses, but progression and recurrence are common and often occur within 1 year. Early evidence shows encouraging activity and durable clinical response for checkpoint inhibitors (CIs), such as durvalumab, as treatment for advanced HCC (Kelley, et al. ASCO 2017) and combined with TACE (Duffy, et al. J Hepatology, 2017). CIs combined with VEGF inhibitors (Cheng, et al. ESMO Asia 2019) also show promise in advanced HCC. Taken together, combining D, VEGF inhibitors, and TACE therapies warrants evaluation in patients with locoregional HCC. EMERALD-1 (NCT03778957) is a randomized, double-blind, placebo-controlled, multicenter phase 3 study assessing efficacy and safety for durvalumab monotherapy when given with either drug-eluting bead (DEB)-TACE or conventional TACE (cTACE) followed by durvalumab with or without bevacizumab therapy in patients with HCC not amenable to curative therapy. 600 patients will be randomized 1:1:1 to Arm A (DEB-TACE or cTACE + durvalumab and following last TACE procedure, durvalumab + placebo), Arm B (DEB-TACE or cTACE + durvalumab followed by durvalumab + bevacizumab), or Arm C (DEB-TACE or cTACE). Durvalumab therapy will begin after at least 7 days following the initial TACE procedure. Durvalumab ± bevacizumab will begin after at least 14 days following the last TACE procedure. Eligible patients must have confirmed HCC not amenable to curative therapy, have Child-Pugh score class A to B7, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients with a history of nephrotic or nephritic syndrome, clinically significant cardiovascular disease, extrahepatic disease, or main portal vein thrombosis (Vp3/Vp4) are excluded. Patients with active (controlled) or past hepatitis virus B or C infection may be enrolled. The primary endpoint is progression-free survival (PFS) for Arm A versus Arm C by blinded independent radiology review using RECIST v1.1. Secondary endpoints include PFS for Arm B versus Arm C, overall survival, health-related quality of life measures, and safety. Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Jubilee Stewart, PhD of Parexel (Hackensack, NJ, USA). AstraZeneca. AstraZeneca.